Literature DB >> 33144445

Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients.

Moonsik Kim1, Yeon Seung Chung1, Kyoung A Kim1, Hyo Sup Shim2.   

Abstract

BACKGROUND/AIM: In recent years, the genomic landscape of neuroendocrine tumors (NETs) of the lung has been investigated. However, more data are necessary to elucidate the heterogeneous nature of NETs, especially in East Asian patients. PATIENTS AND METHODS: A total of 64 patients who underwent surgical resection for lung NETs [26 typical or atypical carcinoid tumors, 21 large-cell neuroendocrine carcinomas (LCNECs), and 19 small-cell lung carcinomas (SCLCs)] were enrolled, and samples from 46 patients were subjected to targeted next-generation sequencing.
RESULTS: Co-mutations of tumor protein p53 (TP53) and RB transcriptional corepressor 1 (RB1) were detected in 15%, 42%, and 93% of carcinoid tumors, LCNECs, and SCLCs, respectively. Oncogenic or targetable genetic alterations identified in this study included mutations of KRAS proto-oncogene (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), ALK receptor tyrosine kinase (ALK), mitogen-activated protein kinase kinase 1 (MAP2K1), and isocitrate dehydrogenase 1 (IDH1), as well as amplifications of erb-b2 receptor tyrosine kinase 2 (ERBB2), fibroblast growth factor receptor 1 (FGFR1), CD274 molecule (CD274), and MYCN proto-oncogene (MYCN). These alterations were more frequently found in high-grade NETs than in carcinoid tumors (33.3% vs. 7.7%). Programmed cell death-ligand 1 expression was strongly associated with the LCNEC subtype among NETs (p=0.002).
CONCLUSION: The mutational status of TP53 and RB1 was significantly associated with NET subtypes in East Asian patients. Targeted therapy or immunotherapy may serve as a treatment option in a subset of patients with high-grade NETs. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Neuroendocrine tumor; PD-L1; RB1; TP53; lung; next-generation sequencing

Mesh:

Year:  2020        PMID: 33144445      PMCID: PMC7811643          DOI: 10.21873/invivo.12176

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  34 in total

Review 1.  PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Authors:  Sylvie Lantuejoul; Ming Sound-Tsao; Wendy A Cooper; Nicolas Girard; Fred R Hirsch; Anja C Roden; Fernando Lopez-Rios; Deepali Jain; Teh-Ying Chou; Noriko Motoi; Keith M Kerr; Yasushi Yatabe; Elisabeth Brambilla; John Longshore; Mauro Papotti; Lynette M Sholl; Erik Thunnissen; Natasha Rekhtman; Alain Borczuk; Lukas Bubendorf; Yuko Minami; Mary Beth Beasley; Johan Botling; Gang Chen; Jin-Haeng Chung; Sanja Dacic; David Hwang; Dongmei Lin; Andre Moreira; Andrew G Nicholson; Masayuki Noguchi; Giuseppe Pelosi; Claudia Poleri; William Travis; Akihiko Yoshida; Jillian B Daigneault; Ignacio I Wistuba; Mari Mino-Kenudson
Journal:  J Thorac Oncol       Date:  2019-12-20       Impact factor: 15.609

2.  Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).

Authors:  B C M Hermans; J L Derks; E Thunnissen; R J van Suylen; M A den Bakker; H J M Groen; E F Smit; R A Damhuis; E C van den Broek; C M Stallinga; G M Roemen; E J M Speel; A-M C Dingemans
Journal:  Lung Cancer       Date:  2019-02-21       Impact factor: 5.705

Review 3.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Authors:  Charles M Rudin; John T Poirier; Lauren Averett Byers; Caroline Dive; Afshin Dowlati; Julie George; John V Heymach; Jane E Johnson; Jonathan M Lehman; David MacPherson; Pierre P Massion; John D Minna; Trudy G Oliver; Vito Quaranta; Julien Sage; Roman K Thomas; Christopher R Vakoc; Adi F Gazdar
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

4.  PD-L1 expression in large cell neuroendocrine carcinoma of the lung.

Authors:  F Eichhorn; A Harms; A Warth; T Muley; H Winter; M E Eichhorn
Journal:  Lung Cancer       Date:  2018-02-06       Impact factor: 5.705

5.  An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.

Authors:  Masafumi Horie; Naoya Miyashita; Johanna Sofia Margareta Mattsson; Yu Mikami; Martin Sandelin; Hans Brunnström; Patrick Micke; Takahide Nagase; Akira Saito
Journal:  J Pathol       Date:  2018-08-13       Impact factor: 7.996

6.  Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.

Authors:  Hye Sook Kim; Jeong Hyeon Lee; Soo Jeong Nam; Chan-Young Ock; Jae-Woo Moon; Chong Woo Yoo; Geon Kook Lee; Ji-Youn Han
Journal:  J Thorac Oncol       Date:  2018-01-31       Impact factor: 15.609

7.  Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Authors:  Wei Zhang; Luc Girard; Yu-An Zhang; Tomohiro Haruki; Mahboubeh Papari-Zareei; Victor Stastny; Hans K Ghayee; Karel Pacak; Trudy G Oliver; John D Minna; Adi F Gazdar
Journal:  Transl Lung Cancer Res       Date:  2018-02

8.  Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.

Authors:  Lynnette Fernandez-Cuesta; Martin Peifer; Xin Lu; Ruping Sun; Luka Ozretić; Danila Seidal; Thomas Zander; Frauke Leenders; Julie George; Christian Müller; Ilona Dahmen; Berit Pinther; Graziella Bosco; Kathryn Konrad; Janine Altmüller; Peter Nürnberg; Viktor Achter; Ulrich Lang; Peter M Schneider; Magdalena Bogus; Alex Soltermann; Odd Terje Brustugun; Åslaug Helland; Steinar Solberg; Marius Lund-Iversen; Sascha Ansén; Erich Stoelben; Gavin M Wright; Prudence Russell; Zoe Wainer; Benjamin Solomon; John K Field; Russell Hyde; Michael Pa Davies; Lukas C Heukamp; Iver Petersen; Sven Perner; Christine Lovly; Federico Cappuzzo; William D Travis; Jürgen Wolf; Martin Vingron; Elisabeth Brambilla; Stefan A Haas; Reinhard Buettner; Roman K Thomas
Journal:  Nat Commun       Date:  2014-03-27       Impact factor: 14.919

9.  Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients.

Authors:  Xu-Chao Zhang; Jun Wang; Guo-Guang Shao; Qun Wang; Xiaotao Qu; Bo Wang; Christopher Moy; Yue Fan; Zayed Albertyn; Xiayu Huang; Jingyu Zhang; Yang Qiu; Suso Platero; Matthew V Lorenzi; Enrique Zudaire; Jennifer Yang; Ying Cheng; Lin Xu; Yi-Long Wu
Journal:  Nat Commun       Date:  2019-04-16       Impact factor: 14.919

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more
  3 in total

1.  Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.

Authors:  Shuwen Zhang; Jingjing Chen; Rui Zhang; Liqin Xu; Yan Wang; Zaixin Yuan; Xiaohui Hou; Jian Feng
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-06       Impact factor: 4.553

Review 2.  Lung neuroendocrine tumors: A systematic literature review (Review).

Authors:  Cornel Savu; Alexandru Melinte; Camelia Diaconu; Ovidiu Stiru; Florentina Gherghiceanu; Ștefan Dragoș Octavian Tudorica; Oana Clementina Dumitrașcu; Angelica Bratu; Irina Balescu; Nicolae Bacalbasa
Journal:  Exp Ther Med       Date:  2021-12-28       Impact factor: 2.447

Review 3.  Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors.

Authors:  Philip T Sobash; Asad Ullah; Nagla Abdel Karim
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.